Ashiya Mona 4
4 · Shattuck Labs, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Shattuck Labs (STTK) Director Ashiya Mona Converts Warrants
What Happened
- Ashiya Mona, a director of Shattuck Labs, reported conversions of derivative securities on June 8, 2026. The filing shows acquisitions of 15,366,490 and 3,073,298 derivative units and matching dispositions of the same amounts — a total of 18,439,788 derivative securities converted. No purchase or sale price is reported (N/A) and no immediate common-stock sale or cash consideration is shown. Footnotes state this reflects the exercise/conversion of Common Warrants into Pre‑Funded Warrants in a private-placement transaction.
Key Details
- Date of transactions: June 8, 2026; Form 4 filed June 9, 2026 (timely).
- Reported amounts: 15,366,490 and 3,073,298 derivative securities acquired and the same amounts disposed (total 18,439,788).
- Price/consideration: N/A (no dollar amounts reported).
- Net change in common shares reported on this filing: 0 (these were conversions of derivative instruments, not open‑market buys/sells of common stock).
- Shares owned after the transaction: not specified in the filing.
- Notable footnotes:
- The conversions relate to a private placement with OrbiMed funds (Common Warrants exchanged for Pre‑Funded Warrants).
- Pre‑Funded Warrants are exercisable any time but subject to a 9.99% beneficial‑ownership blocker; Common Warrants had an expiration tied to clinical‑trial data timing.
- Securities are held of record by OrbiMed funds; OrbiMed Advisors and related GP entities may be deemed to have voting/investment power but disclaim beneficial ownership except for any pecuniary interest.
Context
- These are derivative conversions (warrant exchanges), not standard market purchases or sales of common stock. Converting Common Warrants into Pre‑Funded Warrants changes the type of instrument held and may enable future exercise into common shares, but this filing shows no immediate issuance or sale of common stock.
- The reporting involves institutional OrbiMed entities and contains disclaimers that the filing parties do not assert beneficial ownership beyond any pecuniary interest.
Insider Transaction Report
Form 4
Ashiya Mona
Director
Transactions
- Conversion
Pre-Funded Warrants (right to buy)
[F1][F2][F3][F5]2026-06-08+15,366,490→ 25,477,874 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (15,366,490 underlying) - Conversion
Pre-Funded Warrants (right to buy)
[F1][F2][F4][F5]2026-06-08+3,073,298→ 5,095,575 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (3,073,298 underlying) - Conversion
Common Warrants (right to buy)
[F1][F2][F3][F5]2026-06-08−15,366,490→ 0 total(indirect: See Footnote)Exercise: $1.08→ Common Stock (15,366,490 underlying) - Conversion
Common Warrants (right to buy)
[F1][F2][F4][F5]2026-06-08−3,073,298→ 0 total(indirect: See Footnote)Exercise: $1.08→ Common Stock (3,073,298 underlying)
Holdings
- 5,255,106(indirect: See Footnote)
Common Stock
[F3][F5] - 1,051,021(indirect: See Footnote)
Common Stock
[F4][F5]
Footnotes (5)
- [F1]On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP ("OPI IX") and OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund") in a private placement which closed on August 25, 2025 (the "Closing Date") an aggregate of 6,306,127 shares of the Issuer's common stock ("Shares") and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants.
- [F2]The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
- [F3]These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.
- [F4]These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
- [F5]Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/ Mona Ashiya|2026-06-09